A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer-1

Omparison of the serum OPG level by age and disease status (stage B, C, and D) in healthy controls and patients with PCa. *Age represents mean ± standard deviation.<p><b>Copyright information:</b></p><p>Taken from "A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer"</p><p>http://www.biomedcentral.com/1471-2407/8/224</p><p>BMC Cancer 2008;8():224-224.</p><p>Published online 6 Aug 2008</p><p>PMCID:PMC2527333.</p><p></p

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer-0

2.938 and 3.018 (= 0.087 and 0.082, respectively).<p><b>Copyright information:</b></p><p>Taken from "A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer"</p><p>http://www.biomedcentral.com/1471-2407/8/224</p><p>BMC Cancer 2008;8():224-224.</p><p>Published online 6 Aug 2008</p><p>PMCID:PMC2527333.</p><p></p

A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the role of osteoprotegerin gene <it>(OPG) </it>polymorphisms as genetic modifiers in the etiology of prostate cancer (PCa) and disease progression.</p> <p>Methods</p> <p>Three hundred and sixty one patients with PCa and 195 normal controls were enrolled in the study, and two genetic polymorphisms, <it>149 T/C </it>and <it>950 T/C </it>in the putative promoter region of <it>OPG</it>, were genotyped.</p> <p>Results</p> <p>There was no significant difference in the genotype frequencies between PCa patients and controls (<it>P </it>= 0.939 and 0.294 for <it>149 T/C </it>and <it>950 T/C </it>polymorphisms, respectively). However, those patients with <it>TC </it>and <it>TT </it>genotypes in the <it>950 T/C </it>polymorphism had a significantly increased risk of extraprostatic (age-adjusted odds ratio; aOR = 1.74 and 2.03 for <it>TC </it>and <it>TT </it>genotypes compared with the <it>CC </it>genotype, <it>P </it>= 0.028) and metastatic disease (aOR = 1.72 and 2.76 for <it>TC </it>and <it>TT </it>genotypes compared with the <it>CC </it>genotype, <it>P </it>= 0.009) compared with those with the <it>CC </it>genotype. In addition, analysis of the metastatic PCa patients (Stage D) showed that the presence of the <it>T </it>allele of the <it>OPG 950 T/C </it>polymorphism was an independent risk factor predicting survival by Cox proportional hazard regression analyses (<it>P </it>= 0.031).</p> <p>Conclusion</p> <p>Progression of PCa may be influenced by an intrinsic genetic factor of the host's bone metabolism. The variant <it>C </it>allele of <it>950 T/C </it>in the <it>OPG </it>promoter may play a major role as a genetic safe guard against progression in patients with PCa.</p